Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		Pre-market 08:54:23 am
159.6 USD -4.58% Intraday chart for AbbVie Inc. 159.4 -0.11%
02:52pm Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196 MT
02:31pm Barclays Adjusts Price Target on AbbVie to $187 From $195 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 130,935 189,171 239,371 285,707 273,605 282,631 - -
Enterprise Value (EV) 1 157,739 266,778 306,225 339,749 320,176 334,704 327,364 317,825
P/E ratio 16.8 x 39.4 x 21 x 24.4 x 57 x 31.2 x 24.3 x 20.8 x
Yield 4.96% 4.52% 3.92% 3.53% 3.87% 3.88% 4.07% 4.25%
Capitalization / Revenue 3.94 x 4.13 x 4.27 x 4.92 x 5.04 x 5.14 x 4.89 x 4.57 x
EV / Revenue 4.74 x 5.83 x 5.46 x 5.85 x 5.89 x 6.09 x 5.66 x 5.14 x
EV / EBITDA 8.89 x 11.8 x 10.6 x 11 x 12.5 x 12.6 x 11.6 x 10.3 x
EV / FCF 12.4 x 15.9 x 13.9 x 14 x 14.5 x 17.3 x 13.8 x 12.4 x
FCF Yield 8.1% 6.29% 7.18% 7.14% 6.89% 5.79% 7.22% 8.05%
Price to Book -16.1 x 13.7 x 15.5 x 16.6 x 26.5 x 27 x 24.7 x 20.3 x
Nbr of stocks (in thousands) 1,478,821 1,765,474 1,767,880 1,767,880 1,765,537 1,770,647 - -
Reference price 2 88.54 107.2 135.4 161.6 155.0 159.6 159.6 159.6
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 33,266 45,784 56,122 58,054 54,318 54,994 57,803 61,892
EBITDA 1 17,747 22,642 29,018 30,961 25,545 26,490 28,279 30,756
EBIT 1 15,730 21,976 28,215 30,183 24,793 25,483 27,427 30,042
Operating Margin 47.29% 48% 50.27% 51.99% 45.64% 46.34% 47.45% 48.54%
Earnings before Tax (EBT) 1 8,426 3,398 12,989 13,477 6,250 11,991 14,518 16,669
Net income 1 7,882 4,616 11,542 11,836 4,863 7,780 11,026 13,120
Net margin 23.69% 10.08% 20.57% 20.39% 8.95% 14.15% 19.08% 21.2%
EPS 2 5.280 2.720 6.450 6.630 2.720 5.114 6.567 7.657
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,377 23,638 25,588
FCF margin 38.39% 36.67% 39.18% 41.77% 40.62% 35.23% 40.89% 41.34%
FCF Conversion (EBITDA) 71.97% 74.15% 75.78% 78.32% 86.37% 73.15% 83.59% 83.2%
FCF Conversion (Net income) 162.04% 363.73% 190.52% 204.87% 453.67% 249.05% 214.38% 195.03%
Dividend per Share 2 4.390 4.840 5.310 5.710 5.990 6.191 6.492 6.781
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 14,342 14,886 13,538 14,583 14,812 15,121 12,225 13,865 13,927 14,301 12,310 13,873 14,184 14,773 12,970
EBITDA 1 7,559 7,506 7,156 7,643 8,090 8,072 5,682 6,710 6,706 6,447 5,444 7,136 6,890 7,046 -
EBIT 1 7,336 7,333 6,958 7,440 7,909 7,876 5,503 6,520 6,510 6,260 2,798 6,879 6,700 6,818 6,659
Operating Margin 51.15% 49.26% 51.4% 51.02% 53.4% 52.09% 45.01% 47.02% 46.74% 43.77% 22.73% 49.58% 47.24% 46.15% 51.34%
Earnings before Tax (EBT) 1 - - - - - - 475 2,610 1,953 1,212 1,755 3,209 3,673 3,362 -
Net income 1 3,179 4,044 4,490 924 3,949 2,473 239 2,024 1,778 822 1,369 1,741 1,520 1,572 1,115
Net margin 22.17% 27.17% 33.17% 6.34% 26.66% 16.35% 1.96% 14.6% 12.77% 5.75% 11.12% 12.55% 10.71% 10.64% 8.6%
EPS 2 1.780 2.260 2.510 0.5100 2.210 1.380 0.1300 1.140 1.000 0.4600 0.7700 1.550 1.220 1.117 0.6200
Dividend per Share 2 1.300 1.410 1.410 1.410 1.410 1.480 1.480 1.480 1.480 1.550 1.546 1.543 1.543 1.543 1.605
Announcement Date 10/29/21 2/2/22 4/29/22 7/29/22 10/28/22 2/9/23 4/27/23 7/27/23 10/27/23 2/2/24 4/26/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 26,804 77,607 66,854 54,042 46,571 52,074 44,733 35,194
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.51 x 3.428 x 2.304 x 1.745 x 1.823 x 1.966 x 1.582 x 1.144 x
Free Cash Flow 1 12,772 16,790 21,990 24,248 22,062 19,377 23,638 25,588
ROE (net income / shareholders' equity) -160% 188% 159% 151% 143% 176% 171% 185%
ROA (Net income/ Total Assets) 10.6% 3.85% 15.3% 17.2% 14.5% 11.6% 11.3% 13.5%
Assets 1 74,234 119,840 75,543 68,651 33,641 66,894 97,872 96,877
Book Value Per Share 2 -5.510 7.830 8.710 9.740 5.840 5.910 6.460 7.860
Cash Flow per Share 2 8.980 10.50 12.80 14.00 12.90 15.40 15.60 13.90
Capex 1 552 798 787 695 777 821 850 878
Capex / Sales 1.66% 1.74% 1.4% 1.2% 1.43% 1.49% 1.47% 1.42%
Announcement Date 2/7/20 2/3/21 2/2/22 2/9/23 2/2/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
159.6 USD
Average target price
183 USD
Spread / Average Target
+14.62%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.87% 231B
NOVARTIS AG Stock Novartis AG
+5.23% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-8.83% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
PFIZER, INC. Stock Pfizer, Inc.
-11.77% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. Financials AbbVie Inc.